The value of measuring cysC, β2-microglobulin and neutrophil gelatinase-associated lipocalin as a test panel for detection of early renal damage in lung cancer patients receiving chemotherapy

Abstract

Objective To compare the value of serum cystatin C (CysC), urine β2-microglobulin (β2-MG), and neutrophil gelatinase-associated lipocalin (NGAL) as a test panel with that of traditional indicators, serum Cr and urea, for detection of early renal damage in lung cancer patients after chemotherapy. Methods This prospective study collected data at our hospital on levels of serum cystatin C (CysC), urine β2-microglobulin (β2-MG), and neutrophil-gelatinase associated lipocalin (NGAL) from 63 lung cancer patients aged 60 and over.In addition, levels of traditional indicators including serum Cr and urea were also measured.Participants were divided into three groups: a pre-chemotherapy group, an under chemotherapy group, and a post-chemotherapy group. Results Levels of serum CysC, urine β2-MG, and NGAL in the post-chemotherapy group markedly increased, whereas levels of serum Cr and urea had no significant increase; furthermore, levels of serum CysC, urine β2-MG, and NGAL went up steadily as the time of exposure to chemotherapy drugs increased.Pearson’s test showed that the sensitivity of CysC, beta 2-MG and NGAL as a panel was statistically significant for both the under chemotherapy group and the post-chemotherapy group (χ2=31.32, P=0.00; χ2=60.38, P=0.00). Conclusions Serum CysC, urine β2-MG and NGAL as a panel have good diagnostic value for early renal function damage in lung cancer patients after chemotherapy and are superior to traditional renal function indicators such as serum creatinine and urea. Key words: Lung neoplasm; Chemotherapy protocols; Renal function damage; Neutrophil gelatinase-associated lipocalin; Cystatin C